Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/182346
IPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Myocardial infarction is the main driver of heart failure due to ischemia and subsequent cell death, and cell-based strategies have emerged as promising therapeutic methods to replace dead tissue in cardiovascular diseases. Research in this field has been dramatically advanced by the development of laboratory-induced pluripotent stem cells (iPSCs) that harbor the capability to become any cell type. Like other experimental strategies, stem cell therapy must meet multiple requirements before reaching the clinical trial phase, and in vivo models are indispensable for ensuring the safety of such novel therapies. Specifically, translational studies in large animal models are necessary to fully evaluate the therapeutic potential of this approach; to empirically determine the optimal combination of cell types, supplementary factors, and delivery methods to maximize efficacy; and to stringently assess safety. In the present review, we summarize the main strategies employed to generate iPSCs and differentiate them into cardiomyocytes in large animal species; the most critical differences between using small versus large animal models for cardiovascular studies; and the strategies that have been pursued regarding implanted cells' stage of differentiation, origin, and technical application.
Matèries (anglès)
Citació
Citació
MARTÍNEZ FALGUERA, Daina, IBORRA EGEA, Oriol, GÁLVEZ MONTÓN, Carolina. IPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams. _Biomedicines_. 2021. Vol. 9, núm. 12, pàgs. 1836. [consulta: 25 de febrer de 2026]. [Disponible a: https://hdl.handle.net/2445/182346]